LYNDOR BIOSCIENCES LLC
Samtheo formed Lyndor Biosciences LLC (“Lyndor”) as its first portfolio company. On March 2, 2009, Lyndor acquired the exclusive, world-wide rights to its lead compound, LD-101, from H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida. Lyndor’s interest in the treatment of cancer and development of LD-101 as an effective targeted therapeutic agent for personalized medicine is propelled by the desire to improve cancer treatment, offer patients greater life expectancy and provide a better quality of life.

PUBLICATIONS
Jin Q. Cheng, M.D., Ph.D., Professor, Molecular Oncology Department, and Said M. Sebti, Ph.D., Professor and Chair, Drug Discovery Department, at the H. Lee Moffitt Cancer Center and Research Institute, Inc. are the co-inventors of LD-101. Drs. Cheng and Sebti presented data on LD-101 at the AACR 2008 Annual Meeting in San Diego on April 12-16, 2008. The publication, abstract #1432, is entitled “A Small Molecule Compound Selectively Inhibits Akt, Including AKT1-E17K, Signaling and Tumor Growth in Cancer Cells with Hyperactivated Akt”.